Tissue Culture Core Facility The goal of the this core is to provide UNC Lineberger Comprehensive Cancer Center members with expert services and quality controlled and innovative materials required for basic and clinical research involving in vitro cell culture and related testing services. This core provides services and support not found elsewhere at UNC. The facility has two main """"""""divisions."""""""" The first is Cell Culture, with all of its services, products, and testing. Services are designed and implemented to cover a wide range of user needs, such as large scale cell and metabolite production from cell propagation, monoclonal antibody (Mab) production using standard procedures, and production of gram quantities of Mab using hollow fiber, bioreactor and membrane designed units. Many ofthe Mabs produced are serum- and protein-free and can be used without further concentration or purification. Cell cryopreservation services are available using a programmable rate freezer. Testing for sterility, endotoxin, and mycoplasma are routinely provided. The other """"""""division"""""""" of the core focuses on clinical support through its immortalization of human B-cells using EBV. This area is being increased to Include cell line identification by fingerprinting and karyotyping where required. The facility is led by Stephen Oglesbee, Director, with over 34 years of direct experience. The Core adds value to the Center by providing a range of specialized services, centralized functions, and cost savings and convenience. Highlights of research supported by the core include: high human B-cell transformation rates (over 98%) and the development and testing of new specialized media either already licensed or soon to be managed for the good ofthe UNC LCCC. There are currently >900 cell lines kept on site. Peer-reviewed members (159) account for 80% of the total facility use. In 2009,172 cancer center members (all but 13 are peer -reviewed) from all programs used the core. Future plans include expansion of its human B-cell immortalization program in support of numerous projects with other methods of immortalization of other cell types. Cell line fingerprinting is becoming a newly added service. CCSG funds of $66,895 are requested, representing 5% of total operating costs.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA016086-38
Application #
8594161
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2013-12-01
Budget End
2014-11-30
Support Year
38
Fiscal Year
2014
Total Cost
$170,210
Indirect Cost
$66,183
Name
University of North Carolina Chapel Hill
Department
Type
DUNS #
608195277
City
Chapel Hill
State
NC
Country
United States
Zip Code
27599
Cameron, Jennifer E; Rositch, Anne F; Vielot, Nadja A et al. (2018) Epstein-Barr Virus, High-Risk Human Papillomavirus and Abnormal Cervical Cytology in a Prospective Cohort of African Female Sex Workers. Sex Transm Dis 45:666-672
Lim, Joseph K; Liapakis, Ann Marie; Shiffman, Mitchell L et al. (2018) Safety and Effectiveness of Ledipasvir and Sofosbuvir, With or Without Ribavirin, in Treatment-Experienced Patients With Genotype 1 Hepatitis C Virus Infection and Cirrhosis. Clin Gastroenterol Hepatol 16:1811-1819.e4
Wang, Gary P; Terrault, Norah; Reeves, Jacqueline D et al. (2018) Prevalence and impact of baseline resistance-associated substitutions on the efficacy of ledipasvir/sofosbuvir or simeprevir/sofosbuvir against GT1 HCV infection. Sci Rep 8:3199
Phillips, Bonnie; Van Rompay, Koen K A; Rodriguez-Nieves, Jennifer et al. (2018) Adjuvant-Dependent Enhancement of HIV Env-Specific Antibody Responses in Infant Rhesus Macaques. J Virol 92:
Lianga, Noel; Doré, Carole; Kennedy, Erin K et al. (2018) Cdk1 phosphorylation of Esp1/Separase functions with PP2A and Slk19 to regulate pericentric Cohesin and anaphase onset. PLoS Genet 14:e1007029
Allott, Emma H; Geradts, Joseph; Cohen, Stephanie M et al. (2018) Frequency of breast cancer subtypes among African American women in the AMBER consortium. Breast Cancer Res 20:12
Dhungel, Bal Mukunda; Montgomery, Nathan D; Painschab, Matthew S et al. (2018) 'Discovering' primary effusion lymphoma in Malawi. AIDS 32:2264-2266
Puvanesarajah, Samantha; Nyante, Sarah J; Kuzmiak, Cherie M et al. (2018) PAM50 and Risk of Recurrence Scores for Interval Breast Cancers. Cancer Prev Res (Phila) 11:327-336
Stanley, Christopher C; van der Gronde, Toon; Westmoreland, Kate D et al. (2018) Risk factors and reasons for treatment abandonment among children with lymphoma in Malawi. Support Care Cancer 26:967-973
Dronamraju, Raghuvar; Jha, Deepak Kumar; Eser, Umut et al. (2018) Set2 methyltransferase facilitates cell cycle progression by maintaining transcriptional fidelity. Nucleic Acids Res 46:1331-1344

Showing the most recent 10 out of 1525 publications